Maven Securities LTD trimmed its stake in WAVE Life Sciences Ltd. (NASDAQ:WVE - Free Report) by 79.4% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 35,000 shares of the company's stock after selling 135,000 shares during the quarter. Maven Securities LTD's holdings in WAVE Life Sciences were worth $283,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Squarepoint Ops LLC acquired a new position in shares of WAVE Life Sciences in the 4th quarter valued at $256,000. Principal Financial Group Inc. raised its position in shares of WAVE Life Sciences by 23.9% in the 1st quarter. Principal Financial Group Inc. now owns 308,044 shares of the company's stock worth $2,489,000 after buying an additional 59,399 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of WAVE Life Sciences by 23.3% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 52,392 shares of the company's stock worth $648,000 after buying an additional 9,907 shares during the period. Bank of America Corp DE boosted its holdings in WAVE Life Sciences by 58.5% in the fourth quarter. Bank of America Corp DE now owns 435,896 shares of the company's stock valued at $5,392,000 after acquiring an additional 160,820 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in WAVE Life Sciences by 14.2% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 165,238 shares of the company's stock valued at $2,044,000 after acquiring an additional 20,520 shares during the period. Institutional investors and hedge funds own 89.73% of the company's stock.
WAVE Life Sciences Stock Down 0.6%
NASDAQ WVE opened at $9.45 on Thursday. WAVE Life Sciences Ltd. has a fifty-two week low of $5.04 and a fifty-two week high of $16.74. The business has a 50 day moving average price of $7.81 and a two-hundred day moving average price of $8.06. The stock has a market cap of $1.50 billion, a PE ratio of -10.50 and a beta of -0.95.
WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.02). The firm had revenue of $8.70 million for the quarter, compared to the consensus estimate of $11.52 million. Sell-side analysts anticipate that WAVE Life Sciences Ltd. will post -1.14 EPS for the current fiscal year.
Insiders Place Their Bets
In other news, Director Christian O. Henry sold 9,670 shares of WAVE Life Sciences stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $8.81, for a total transaction of $85,192.70. Following the sale, the director directly owned 29,645 shares of the company's stock, valued at approximately $261,172.45. The trade was a 24.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gregory L. Verdine sold 30,000 shares of the business's stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $6.95, for a total value of $208,500.00. Following the completion of the transaction, the director owned 282,517 shares in the company, valued at approximately $1,963,493.15. This trade represents a 9.60% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 44,542 shares of company stock worth $336,323 in the last quarter. 23.98% of the stock is owned by corporate insiders.
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on WVE. Canaccord Genuity Group began coverage on WAVE Life Sciences in a report on Monday, August 4th. They issued a "buy" rating and a $19.00 price objective on the stock. Wedbush reissued an "outperform" rating and set a $18.00 target price on shares of WAVE Life Sciences in a research report on Monday, June 23rd. Wall Street Zen cut shares of WAVE Life Sciences from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Citigroup started coverage on shares of WAVE Life Sciences in a research note on Wednesday, July 16th. They set a "buy" rating and a $16.00 price objective for the company. Finally, Oppenheimer started coverage on shares of WAVE Life Sciences in a research report on Monday, July 28th. They issued an "outperform" rating and a $24.00 price objective for the company. Fourteen investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, WAVE Life Sciences presently has a consensus rating of "Moderate Buy" and an average target price of $20.27.
Check Out Our Latest Report on WAVE Life Sciences
About WAVE Life Sciences
(
Free Report)
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
Read More
Want to see what other hedge funds are holding WVE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for WAVE Life Sciences Ltd. (NASDAQ:WVE - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider WAVE Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and WAVE Life Sciences wasn't on the list.
While WAVE Life Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access